Stock Evaluator: AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. ABCL

$9.69 -0.78 -7.45%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 4,233,024
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Commentary & Analysis


Financial Summary

Share Statistics ABCL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,164.9 $3,333.2 62%
Shares Out (Mil) 318.1 107.2 83%
Institutional Ownership 59.3% 88.4% 38%
Float (Mil) 224.5 79.2 75%
Beta 1.59 1.15 84%
Avg Daily Volume (000s) 3,009 958 86%
Price Change
(52-week)
168.4% 81.2% 99%
Growth ABCL Industry
Median
Percentile
(All Stocks)
Sales (5yr) (20.3%) 7.5% 2%
Net Income (5yr) (26.4%) (12.9%) 16%
EPS (5yr) (25.3%) 1.4% 10
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.1%) (15.0%) 51%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 10 9
Current EPS ($0.155) ($0.609) ($0.704)
Month Ago EPS ($0.172) ($0.674) ($0.763)
# Rev Up 0 0 0
# Rev Down 1 0 0
Three Months Ago EPS ($0.170) ($0.656) ($0.715)
Year/Year Chg 19.2% 24.3% 56.1%
Financials ABCL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $68 $816 22%
Net Income (TTM) (Mil) ($148) ($24) 8%
EPS (TTM) ($0.484) ($0.300) 27%
Operating Cash Flow (TTM) (Mil) ($15) $79 17%
Net Cash Flow (TTM) (Mil) $80 $4 75%
Long-Term Debt (Q1) (Mil) $128 $263 46%
Enterprise Value (Q1) (Mil) $2,969 $3,667 55%
Valuation ABCL Industry
Median
Percentile
(All Stocks)
P/B 2.97 2.97 71%
P/E na 33.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 6.4 na
Ratios ABCL Industry
Median
Percentile
(All Stocks)
Gross Margin (174.5%) 47.5% 1%
Net Margin (218.6%) (3.5%) 4%
ROA (10.4%) (4.5%) 24%
ROE (14.6%) (3.6%) 25%
Liabilities to Assets 29.2% 40.9% 20%
F-Score 6 5 67%

AbCellera Biologics Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors